# Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS

> **NCT01133275** · PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 28 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- MDS

## Interventions

- **DRUG:** Prednisone
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01133275
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04-28
- **Primary completion:** 2015-01-31
- **Final completion:** 2019-11-21
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2019-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01133275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01133275, "Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01133275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*